Newsletter registration

Austria.
Bridge to New Markets.

Boehringer Ingelheim

Logo
Austria stands out due to its long-term reliable and stable conditions. These
features are particularly important for a research-based company such as
Boehringer Ingelheim. Furthermore, Vienna is a city with a good research
infrastructure and a high quality of life, and is thus also an interesting place
for highly qualified employees from Austria and abroad.

Boehringer Ingelheim was also present in Austria before the fall of the Iron Curtain and coordinates these activities from its Vienna base. Today Boehringer Ingelheim Regional Center Vienna (RCV) has 1,400 employees and is responsible for the pharmaceutical business and clinical research in more than 30 countries in Central and Eastern Europe and Central Asia. Its primary tasks are to build up and expand local organizations and structures, coordinate product launches and provide market support, plan and organize clinical research as well as to prepare specialized medical information and make it available.

In addition, Vienna serves as the company’s global cancer research center as well as one of its three sites for the research, development and production of biopharmaceuticals. Boehringer Ingelheim RCV currently ranks among the most important research-oriented pharmaceutical companies in the Austrian life sciences sector. 

www.boehringer-ingelheim.at

Share on Facebook Share on Facebook Share on Twitter Share on Twitter

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • B2B Software Days

    25.-26.04.2017, Vienna, Austria

Austria Map

Find the perfect location for your company

Vienna is the driving force for innovations in our company,
and one of the growth drivers.

Ottobock Austria

Logo
More testimonials

news from the business location Austria

Zika Virus: Testing for Austria vaccine begins

A promising vaccine for the Zika virus is now being tested by Themis Bioscience GmbH, a specialized biotech company developing prophylactic vaccines against emerging tropical infectious diseases. After recent progress with the development of a Chikungunya vaccine the company succeeded in swiftly adapting their proprietary vaccine technology for their Zika vaccine program. This program is based on a live attenuated recombinant vaccine that promises a fast and effective immune response.

Foreign companies as a driving force for Austria

Austria is a very successful country economically speaking. Only Luxembourg, Ireland and the Netherlands have a higher per capita GDP in the EU. Domestic companies mainly assert themselves as market leaders in small niches, are highly productive and export almost everywhere in the world. This is something which is well known, at least within Austria itself.

More news All blog posts